Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity

Cancer Detection and Prevention

Volumn 26, Issue 4, 2002, Pages 275-291

  Hodge, James W ^a   Grosenbach, Douglas W ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunotherapy; Tumor antigens; Vaccines

Indexed keywords

TUMOR ANTIGEN;

ANIMAL; ANTIGEN PRESENTING CELL; DENDRITIC CELL; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASM; PHYSIOLOGY; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; DENDRITIC CELLS; GENETIC VECTORS; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES;

EID: 0036993763     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00095-8     Document Type: Review

References (91)

1. Pardoll DM. Cancer vaccines. Nat Med 1998;4:525-31.
2. Chen CH, Wu TC. Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 1998;5:231-52.
3. + T cells after gene gun immunization. J Exp Med 1998;188:1075-82.
4. Philip R, Brunette E, Ashton J, et al. Transgene expression in dendritic cells to induce antigen-specific cytotoxic T cells in healthy donors. Cancer Gene Ther 1998;5:236-46.
5. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic cell-based vaccines. Cancer Immunol Immunother 1998;46:82-7.
6. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996;93:11341-8.
7. Schlom J, Panicali D. Recombinant poxvirus vaccines. In: Rosenberg SA, editor. Biologic therapy of cancer: principles and practice. 3rd ed. Philadelphia: Lippencott; 2000. p. 686-94.
8. Krieg AM, Yi A-K, Hartmann G. Mechanisms and therapeutic applications of immune stimulatory CpG DNA. Pharmacol Ther 1999;84:113-20.
9. Fenner F. Nature, nurture and my experience with smallpox eradication. Med J Aust 1999;171:638-41.
10. Somogyi P, Frazier J, Skinner MA. Fowlpox virus host range restriction: gene expression, DNA replication and morphogenesis in non-permissive mammalian cells. Virology 1993;197:439-44.
11. Belshe RB, Gorse GJ, Mulligan MJ, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998;12:2407-15.
12. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120. HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 1998;177:1230-46.
13. Cadoz M, Strady A, Meignier B, et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992;339:1429-32.
14. Taylor J, Tartaglia J, Riviere M, et al. Applications of canarypox (ALVAC) vectors in human and veterinary vaccination. Dev Biol Stand 1994;82:131-5.
15. Marshall JL, Hawkins MJ, Tsang KY, et al. Phase I study in cancer patients of a replication-defective avipox (ALVAC) recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999;17:332-7.
16. von Mehren M, Arlen P, Tsang KY, et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000;6:2219-28.
17. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant non-replicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-73.
18. Horig H, Lee DS, Conkright W, et al. Phase I clinical trial of a recombinant canarypox virus (ALVAC) vaccine expressing human carcinoembryonic antigen (CEA) and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000;49:504-14.
19. von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181-91.
20. Salem RR, Wolf BC, Sears HF, et al. Expression of colorectal carcinoma associated antigens in colonic polyps. J Surg Res 1993;55:249-55.
21. Robbins PF, Eggensperger D, Qi C-F, et al. Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas. Int J Cancer 1993;53:892-7.
22. Guadagni F, Roselli M, Cosimelli M, et al. Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation. Int J Cancer 1997;72:949-54.
23. Hodge JW, Schlom J. Carcinoembryonic antigen (CEA) as a model for immunotherapy using recombinant vaccines. In: Stanners CP, editor. Cell adhesion and communication mediated by the CEA family: basic and clinical perspectives. Amsterdam: Harwood; 1998. p. 223-36.
24. Schlom J. Carcinoembryonic antigen (CEA) peptides and vaccines for carcinoma. In: Kast M, editor. Peptide-based cancer vaccines. Austin (TX): Landes Bioscience; 2000. p. 90-105.
25. Kaufman HL, Schlom J. Vaccines for colon cancer. In: Stern P, Beverly P, Carroll M, editors. Cancer vaccines. Cambridge (UK): Cambridge University Press; 2000.
26. Rudert F, Saunders AM, Rebstock S, et al. Characterization of murine carcinoembryonic antigen gene family members. Mamm Genome 1992;3:262-73.
27. Zimmermann W. The nature and expression of the rodent CEA families: evolutionary considerations. In: Stanners CP, editor. Cell adhesion and communication mediated by the CEA family: basic and clinical perspectives. Amsterdam: Harwood; 1998. p. 31-55.
28. Eades-Perner A-M, Zimmermann W. Carcinoembryonic antigen-transgenic mice: a model for tumor immunotherapy. Tumor Biol 1995;16:56-61.
29. Kass E, Schlom J, Thompson J, et al. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59:676-83.
30. Mizobata S, Tompkins K, Simpson JF, et al. Induction of cytotoxic T cells and their anti-tumor activity in mice transgenic for carcinoembryonic antigen. Cancer Immunol Immunother 2000;49:285-95.
31. Xiang R, Silletti S, Lode HN, et al. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin Cancer Res 2001;7(Suppl):856s-64s.
32. Bei R, Kantor J, Kashmiri SVS, et al. Enhanced immune responses and anti-tumor activity by baculovirus recombinant CEA in mice primed with the recombinant vaccinia-CEA. J Immunother 1994;16:275-82.
33. Hodge JW, McLaughlin JP, Kantor JA, et al. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and anti-tumor responses. Vaccine 1997;16:759-68.
34. Grosenbach DW, Barrientos JC, Schlom J, et al. Synergy of vaccine strategies to amplify antigen-specific immune responses and anti-tumor effects. Cancer Res 2001;61:4497-505.
35. Marshall JL, Tsang K, Arlen P, et al. Phase I trial to determine the toxicity and immunologic efficacy of the addition of GM-CSF (GM) and IL-2 to the combination of vaccinia-CEA (V) and ALVAC-CEA (A) administered as a prime and boost in patients (PTS) with advanced CEA-bearing cancers. In: Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology, vol. 20, part 1. San Francisco, CA, 12-15 May 2001. p. 272a [abstract no. 1087].
36. Schlom J. Strategies for the use of recombinant vaccines in cancer therapy. In: Innovative strategies for immune modulation of host responses. In: Proceedings of the 1998 National Immunology Meeting. Bodega Bay, CA, 1998. p. 35-50.
37. Kass E, Panicali DL, Mazzara G, et al. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61:206-14.
38. Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997;23:1094-7.
39. Tartaglia J, Excler JL, El Habib R, et al. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses 1998;14(Suppl):S291-8.
40. Allen TM, Vogel TU, Fuller DH, et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 2000;164:4968-78.
41. Pancholi P, Liu Q, Tricoche N, et al. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and non-structural proteins. J Infect Dis 2000;182:18-27.
42. Irvine KR, Chamberlain RS, Shulman EP, et al. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997;89:1595-601.
43. Chen L, Linsley PS, Hellstrom KE. Co-stimulation of T cells for tumor immunity. Immunol Today 1993;14:483-6.
44. Gollob JA, Li J, Reinherz EL, Ritz J. CD2 regulates responsiveness of activated T cells to interleukin-12. J Exp Med 1995;182:721-31.
45. Gollob JA, Li J, Kawasaki H, et al. Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T-cell activation by IL-12. J Immunol 1996;157:1886-93.
46. Borrego F, Robertson MJ, Ritz J, et al. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology 1999;97:159-65.
47. Schlom J, Hodge JW. The diversity of T-cell co-stimulation in the induction of anti-tumor immunity: vaccines and vaccination. Immunol Rev 1999;170:73-84.
48. Watts TH, DeBenedette MA. T-cell co-stimulatory molecules other than CD28. Curr Opin Immunol 1999;11:286-93.
49. + T-cell help mediated by CD40/CD40L interaction. J Clin Invest 2000;105:1623-30.
50. Bauch A, Alt FW, Crabtree GR. The cytoskeleton in lymphocyte signaling. Adv Immunol 2000;75:89-114.
51. Mueller DL. T cells: a proliferation of co-stimulatory molecules. Curr Biol 2000;10:R227-30.
52. Mahajan S, Gollob JA, Ritz J. CD2 stimulation leads to the delayed and prolonged activation of STAT1 in T cells but not NK cells. Exp Hematol 2001;29:209-20.
53. Hodge JW, Schlom J. Comparative studies of a retrovirus versus a poxvirus vector in whole-tumor-cell vaccines. Cancer Res 1999;59:5106-11.
54. Hodge JW, Abrams S, Schlom J. Induction of anti-tumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 co-stimulatory molecules. Cancer Res 1994;54:5552-5.
55. Kalus RM, Kantor JA, Gritz L, et al. The use of combination vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell co-stimulation. Vaccine 1999;17:893-903.
56. Akagi J, Hodge JW, McLaughlin JP, et al. Therapeutic anti-tumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell co-stimulatory molecule B7. J Immunother 1997;120:38-47.
57. Uzendoski K, Kantor JA, Abrams S, et al. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of anti-tumor responses. Hum Gene Ther 1997;8:851-60.
58. Lorenz MGO, Kantor JA, Schlom J, et al. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). Hum Gene Ther 1999;10:1095-103.
59. Lorenz MGO, Kantor JA, Schlom J, et al. Induction of anti-tumor immunity elicited by recombinant vaccinia virus expressing murine leukocyte function associated antigen-3 (LFA-3). Hum Gene Ther 1999;10:623-31.
60. + T lymphocytes. J Immunol 1992;148:1985-92.
61. Parra E, Wingren AG, Hedlund G, et al. Human naive and memory T-helper cells display distinct adhesion properties to ICAM-1, LFA-3 and B7 molecules. Scand J Immunol 1993;38:508-14.
62. Wingren AG, Parra E, Varga M, et al. T-cell activation pathways: B7, LFA-3 and ICAM-1 shape unique T-cell profiles. Crit Rev Immunol 1995;15:235-53.
63. Hodge JW, Sabzevari H, Yafal AG, et al. A triad of co-stimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800-7.
64. Steinman RM, Pack M, Inaba K. Dendritic cell development and maturation. Adv Exp Med Biol 1997;417:1-6.
65. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
66. Hodge JW, Rad AN, Grosenbach DW, et al. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of co-stimulatory molecules. J Natl Cancer Inst 2000;92:1228-39.
67. Bernhard H, Huseby ES, Hand SL, et al. Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T-cell responses, despite upregulation of MHC class II expression. Immunobiology 2000;201:568-82.
68. Murphy GP, Tjoa BA, Simmons S J, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999;38:73-8.
69. Fallarino F, Uyttenhove C, Boon T, et al. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. Int J Cancer 1999;80:324-33.
70. Porgador A, Snyder D, Gilboa E. Induction of anti-tumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156:2918-26.
71. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor α. J Exp Med 1994;79:1109-18.
72. Hodge JW, Grosenbach DW, Rad AN, et al. Enhancing the potency of peptide-pulsed antigen-presenting cells by vector-driven hyperexpression of a triad of co-stimulatory molecules. Vaccine 2001;19:3552-67.
73. Rad AN, Schlom J, Hodge JW. Vector-driven hyperexpression of a triad of co-stimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors. Crit Rev Oncol Hematol 2001;39:43-57.
74. Zhu MZ, Marshall J, Cole D, et al. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res 2000;6:24-33.
75. Foon KA, John WJ, Chakraborty M, et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 1999;17:2885-9.
76. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001;98:8809-14.
77. Samanci A, Yi Q, Fagerberg J, et al. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol Immunother 1998;47:131-42.
78. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-90 [see comments].
79. Tsang KY, Zhu M, Nieroda CA, et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res 1997;3:2439-49.
80. Alters SE, Gadea JR, Sorich M, et al. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire. J Immunother 1998;21:17-26.
81. Eades-Perner AM, van der Putten H, Hirth A, et al. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 1994;54:4169-76.
82. McLaughlin JP, Schlom J, Kantor JA, et al. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996;56:2361-7.
83. Chamberlain RS, Carroll MW, Bronte V, et al. Co-stimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 1996;56:2832-6.
84. Carroll MW, Overwijk WW, Surman DR, et al. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin-12 and a model tumor antigen. J Natl Cancer Inst 1998;90:1881-7.
85. Kaufman HL, Rao JB, Irvine KR, et al. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J Immunother 1999;22:489-96.
86. Carroll MW, Overwijk WW, Chamberlain RS, et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 1997;15:387-94.
87. Rao JB, Chamberlain RS, Bronte V, et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol 1996;156:3357-65.
88. Sivanandham M, Shaw P, Bernik SF, et al. Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7-1 and interleukin-2 induce anti-tumor response in syngeneic mice. Cancer Immunol Immunother 1998;46:261-7.
89. Qin H, Chatterjee SK. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum Gene Ther 1996;7:1853-60.
90. Gnant MF, Puhlmann M, Bartlett DL, et al. Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases. Ann Surg 1999;230:352-60 [discussion: p. 351-60].
91. Gnant MF, Puhlmann M, Alexander Jr HR, et al. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res 1999;59:3396-403.